eGFR — MDRD study equation
Estimated glomerular filtration rate using the 4-variable MDRD equation.
When to use
- Staging chronic kidney disease when a laboratory reports eGFR with the MDRD equation, and for comparison with historical results.
- CKD-EPI 2021 is more accurate above 60 mL/min/1.73 m² and is preferred for new assessments.
Formula
eGFR = 175 × Scr^−1.154 × age^−0.203 × 0.742 (if female) × 1.212 (if Black); Scr in mg/dL, standardised to IDMS.
Pearls and pitfalls
- MDRD systematically underestimates GFR above roughly 60 mL/min/1.73 m², which is why many laboratories only report values up to "≥60".
- The race coefficient is no longer recommended; major nephrology and laboratory bodies have moved to race-free equations.
- Not validated in acute kidney injury, pregnancy, extremes of body size, or in children.
References
- Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–70.
- Levey AS, et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol. 2005;16:69A.
- Delgado C, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021;32(12):2994–3015.
The Modification of Diet in Renal Disease (MDRD) equation for estimating the Glomerular Filtration Rate (eGFR) is:
eGFR = 175 × (Scr)^-1.154 × (Age)^-0.203 × (0.742 if female) × (1.212 if African American)
The Modification of Diet in Renal Disease (MDRD) equation is a widely used tool for estimating the glomerular filtration rate (eGFR), which assesses kidney function. Developed from the MDRD study, this equation incorporates variables such as serum creatinine, age, sex, and race to provide an eGFR value normalized to a standard body surface area of 1.73 m².
Advantages of MDRD eGFR
Clinical utility: The MDRD equation has been instrumental in identifying and staging chronic kidney disease (CKD), facilitating early intervention and management.
Standardization: Its widespread adoption has led to standardized reporting of eGFR in clinical laboratories, enhancing consistency in patient care.
Non-Invasiveness: The calculation relies on readily available clinical parameters, eliminating the need for more invasive and costly direct measurements of GFR.
Limitations of MDRD eGFR
Accuracy at Higher GFR Levels: The MDRD equation tends to underestimate GFR in individuals with near-normal or mildly reduced kidney function (eGFR >60 mL/min/1.73 m²), potentially leading to misclassification of CKD stages.
Population Specificity: The equation was derived from a study population primarily consisting of individuals with CKD, limiting its accuracy when applied to healthy populations or those with acute kidney injury.
Influence of Muscle Mass and Diet: Serum creatinine levels, a key component of the MDRD equation, can be affected by factors such as muscle mass, diet, and certain medications, potentially impacting the accuracy of eGFR estimations.
Ethnic and racial Variations: The equation includes adjustments for race, particularly for individuals of African descent, which may not accurately reflect the diversity within racial groups and can lead to misestimations.
Clinical implications
While the MDRD eGFR calculator has significantly advanced the detection and management of CKD, clinicians should be aware of its limitations. In cases where precise GFR assessment is critical, especially in individuals with near-normal kidney function, alternative equations like the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation may offer improved accuracy. Additionally, considering factors such as patient demographics, muscle mass, and clinical context is essential when interpreting eGFR results to ensure appropriate clinical decision-making.